Drugs /

methoxyamine

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable small molecule inhibitor with potential adjuvant activity. Methoxyamine covalently binds to apurinic/apyrimidinic (AP) DNA damage sites and inhibits base excision repair (BER), which may result in an increase in DNA strand breaks and apoptosis. This agent may potentiate the anti-tumor activity of alkylating agents.

Clinical Trials

View Clinical Trials for methoxyamine

Methoxyamine has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating methoxyamine, 1 is phase 1/phase 2 (1 open).

Malignant solid tumor, peritoneal mesothelioma, and pleural mesothelioma are the most common diseases being investigated in methoxyamine clinical trials [2].

Drug Details

Synonyms [2]:
o-methylhydroxylamine, trc102, methoxylamine, methoxyamine
NCIT ID [1]:
C78084

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.